Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 221

1.

The risk associated with aprotinin in cardiac surgery.

Mangano DT, Tudor IC, Dietzel C; Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation.

N Engl J Med. 2006 Jan 26;354(4):353-65.

2.

Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery.

Mangano DT, Miao Y, Vuylsteke A, Tudor IC, Juneja R, Filipescu D, Hoeft A, Fontes ML, Hillel Z, Ott E, Titov T, Dietzel C, Levin J; Investigators of The Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation.

JAMA. 2007 Feb 7;297(5):471-9.

PMID:
17284697
3.

A comparison of aprotinin and lysine analogues in high-risk cardiac surgery.

Fergusson DA, Hébert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, Teoh K, Duke PC, Arellano R, Blajchman MA, Bussières JS, Côté D, Karski J, Martineau R, Robblee JA, Rodger M, Wells G, Clinch J, Pretorius R; BART Investigators.

N Engl J Med. 2008 May 29;358(22):2319-31. doi: 10.1056/NEJMoa0802395. Epub 2008 May 14. Erratum in: N Engl J Med. 2010 Sep 23;363(13):1290.

4.

Tranexamic acid and aprotinin in low- and intermediate-risk cardiac surgery: a non-sponsored, double-blind, randomised, placebo-controlled trial.

Later AF, Maas JJ, Engbers FH, Versteegh MI, Bruggemans EF, Dion RA, Klautz RJ.

Eur J Cardiothorac Surg. 2009 Aug;36(2):322-9. doi: 10.1016/j.ejcts.2008.11.038. Epub 2009 Feb 27.

PMID:
19250838
5.

Risks of harms using antifibrinolytics in cardiac surgery: systematic review and network meta-analysis of randomised and observational studies.

Hutton B, Joseph L, Fergusson D, Mazer CD, Shapiro S, Tinmouth A.

BMJ. 2012 Sep 11;345:e5798. doi: 10.1136/bmj.e5798. Review.

6.

The effect of aprotinin on outcome after coronary-artery bypass grafting.

Shaw AD, Stafford-Smith M, White WD, Phillips-Bute B, Swaminathan M, Milano C, Welsby IJ, Aronson S, Mathew JP, Peterson ED, Newman MF.

N Engl J Med. 2008 Feb 21;358(8):784-93. doi: 10.1056/NEJMoa0707768.

7.

The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery.

Karkouti K, Wijeysundera DN, Yau TM, McCluskey SA, Tait G, Beattie WS.

Anesth Analg. 2010 Jan 1;110(1):21-9. doi: 10.1213/ANE.0b013e3181c0ea6d. Epub 2009 Nov 12.

PMID:
19910626
8.

Fibrinolytic inhibitors in off-pump coronary surgery: a prospective, randomized, double-blind TAP study (tranexamic acid, aprotinin, placebo).

Vanek T, Jares M, Fajt R, Straka Z, Jirasek K, Kolesar M, Brucek P, Maly M.

Eur J Cardiothorac Surg. 2005 Oct;28(4):563-8.

PMID:
16125959
9.

Aprotinin in cardiac surgery patients: is the risk worth the benefit?

Stamou SC, Reames MK, Skipper E, Stiegel RM, Nussbaum M, Geller R, Robicsek F, Lobdell KW.

Eur J Cardiothorac Surg. 2009 Nov;36(5):869-75. doi: 10.1016/j.ejcts.2009.04.053. Epub 2009 Sep 25.

PMID:
19782574
10.

Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin.

Dietrich W, Spannagl M, Boehm J, Hauner K, Braun S, Schuster T, Busley R.

Anesth Analg. 2008 Nov;107(5):1469-78. doi: 10.1213/ane.0b013e318182252b.

PMID:
18931201
11.

Aprotinin during coronary-artery bypass grafting and risk of death.

Schneeweiss S, Seeger JD, Landon J, Walker AM.

N Engl J Med. 2008 Feb 21;358(8):771-83. doi: 10.1056/NEJMoa0707571.

12.

[Aprotinin in cardiac surgery: more risks than usefulness?].

Bremerich DH, Strametz R, Kirchner R, Moritz A, Zwissler B.

Anaesthesist. 2006 Sep;55(9):989-92, 994-6. German.

PMID:
16874472
13.

The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis.

Henry D, Carless P, Fergusson D, Laupacis A.

CMAJ. 2009 Jan 20;180(2):183-93. doi: 10.1503/cmaj.081109. Epub 2008 Dec 2. Review.

14.

Mortality associated with administration of high-dose tranexamic acid and aprotinin in primary open-heart procedures: a retrospective analysis.

Sander M, Spies CD, Martiny V, Rosenthal C, Wernecke KD, von Heymann C.

Crit Care. 2010;14(4):R148. doi: 10.1186/cc9216. Epub 2010 Aug 3.

15.

The blood sparing effect and the safety of aprotinin compared to tranexamic acid in paediatric cardiac surgery.

Breuer T, Martin K, Wilhelm M, Wiesner G, Schreiber C, Hess J, Lange R, Tassani P.

Eur J Cardiothorac Surg. 2009 Jan;35(1):167-71; author reply 171. doi: 10.1016/j.ejcts.2008.09.038. Epub 2008 Nov 21.

PMID:
19027313
16.

Use of aprotinin in cardiac surgery: effectiveness and safety in a population-based study.

Jakobsen CJ, Søndergaard F, Hjortdal VE, Johnsen SP.

Eur J Cardiothorac Surg. 2009 Nov;36(5):863-8. doi: 10.1016/j.ejcts.2009.05.040. Epub 2009 Sep 25.

PMID:
19782573
17.

The risks of aprotinin and tranexamic acid in cardiac surgery: a one-year follow-up of 1188 consecutive patients.

Martin K, Wiesner G, Breuer T, Lange R, Tassani P.

Anesth Analg. 2008 Dec;107(6):1783-90. doi: 10.1213/ane.0b013e318184bc20.

PMID:
19020118
18.

Coronary artery bypass grafting after aprotinin: are we doing better?

Beckerman Z, Shopen Y, Alon H, Cohen O, Nir RR, Adler Z, Bolotin G.

J Thorac Cardiovasc Surg. 2013 Jan;145(1):243-8. doi: 10.1016/j.jtcvs.2012.09.032. Epub 2012 Oct 13.

19.

Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery.

Brown JR, Birkmeyer NJ, O'Connor GT.

Circulation. 2007 Jun 5;115(22):2801-13. Epub 2007 May 28.

20.

Current antifibrinolytic therapy for coronary artery revascularization.

Trudell J, McMurdy N.

AANA J. 2008 Apr;76(2):121-4. Review.

PMID:
18478817
Items per page

Supplemental Content

Write to the Help Desk